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1. Introduction 
Therapeutic management of prostate cancer has become complex, multidisciplinary and 
stage-specific. (Heidenereich et al., 2011) Based on PSA level, histopathological grading 
and clinical staging, prostate cancer is classified as low-, intermediate- and high risk for 
disease recurrence. The risk status often plays a major role in deciding further therapy. 
(Kirby & Madhavan, 2010) It is usually impossible to state that one therapy is superior to 
another because of the lack of randomized controlled trials. However some 
recommendations can be made. (Heidenereich et al., 2011, Aus et al. 2001) Based on 
European Association of Urology recommendations in 2010, patients with low-risk (PSA 
≤10 ng/ml, Gleason score <6 and cT1c-cT2a) or intermediate risk prostate cancer (PSA 
10.1-20 ng/ml, Gleason score 7 or cT2b-c) are to be treated interdisciplinary with an 
urologist and a radiation oncologist. Treatment options for these patients vary from 
watchful waiting and active surveillance to radical prostatectomy or definitive 
radiotherapy. Multidisciplinary tumor board is needed when discussing neoadjuvant and 
adjuvant treatment options in high-risk prostate cancer patients (PSA>20ng/ml, Gleason 
score 8-10 or ≥cT3a) (Heidenereich et al., 2011, Choe & Liauw, 2010). 
Radiotherapy is widely used as curative treatment modality for prostate cancer. There is a 
diverse array of radiotherapeutic strategies that can be effectively used to treat both organ-
confined and locally advanced disease, alone or in combination with androgen-deprivation 
therapy. Furthermore, it has also a significant role in post-prostatectomy setting, as adjuvant 
or salvage radiotherapy. 
In recent decades, radiotherapy in prostate cancer has undergone significant clinical and 
technological advances that aim to optimize cancer control outcomes while minimizing 
treatment morbidity. (Choe & Liauw, 2010, Hayden et al., 2010) 
2. External-beam radiotherapy in prostate cancer 
External-beam radiotherapy has a very long history in the curative treatment of prostate 
cancer. It is proven and most extensively used radiation modality. As a flexible, 
noninvasive, outpatient therapy, external-beam radiotherapy can be used in all stages of 
prostate cancer. (Hayden et al., 2010) It is based on daily delivery of radiation to a target 
volume using high-energy radiation beams from linear accelerators (or cobalt machines) 
over a course of 7 to 9 weeks. 
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In the last 30 years it has undergone a long, improving path from conventional, two-
dimensional radiotherapy to intensity-modulated and image-guided radiotherapy and 
onwards. In low-risk prostate cancer its efficacy appears to be comparable to that of radical 
prostatectomy but with different toxicities (Choe & Liauw, 2010). For patients not suitable 
for surgery, external-beam radiotherapy will be the treatment of choice in most cases, alone 
or combined with androgen-deprivation therapy. 
2.1 Conventional radiotherapy 
Introducing high-energy radiotherapy machines it become possible to deliver tumoricidal 
doses to target volume while minimizing damage to the skin and adjacent organs. 
Historically, various techniques have been used, ranging from parallel anteroposterior-
/posteroanterior (AP/PA) portals to lateral portals (box technique) or rotational fields to 
irradiate or supplement the dose to the prostate. (Chao et al, 2002) Due to the difficulty of 
localizing the prostate gland, a large volume was treated to ensure proper coverage. More of 
the surrounding tissues were included in the treated volume so the safely applicable dose 
was limited to 60-65Gy. (Choe & Liauw, 2010) 
The treatment fields for prostate cancer were simulated and designed on plane films and 
using bony markers with the patient in the supine position. Rectum and bladder were 
marked by intraluminal injection of iodinated contrast. Small intestine was marked with 
barium contrast ingested per os one hour prior to simulation.  
If the external-beam radiotherapy was applied to the prostate only (local technique), the field 
size was approximately 8x10 cm for T1 and T2 tumors, 10x12 cm or 12x14 cm for T3 and T4 
prostate cancer. Patients younger than 71 years of age with clinical T1c, T2a, and Gleason score 
more than 7 and PSA 20ng/ml or more, as well as patients with T2b, c T3 and T4 were treated 
to the whole pelvis with the field size of 15x15 cm, or 15x18 cm to cover the common iliac 
nodes. The inferior margin of the field usually was 1.5 cm distal to the junction of the prostatic 
and membranous urethra that is at or caudal to the bottom of the ischial tuberosities. The 
lateral margins were approximately 1 to 2 cm from the lateral bony pelvis. 
 
   
           (a)        (b)   
Fig. 1. Simulation AP radiograph for field verification (a) size 12x12 cm and (b) 14x14 cm 
Low field border is on the lower border of ishiadic bone and the field centre on the 
symphisis. Barium contrast in bowels (With thanks to the Institute for oncology and 
radiology of Serbia, Belgrade) 
www.intechopen.com
 Radiotherapy in Prostate Cancer 
 
171 
The initial lateral fields included a volume similar to that treated with AP/PA portals. The 
anterior margin was 1.5 cm posterior to the projection of the anterior cortex of the pubic 
symphisis. Posteriorly, the fields included the pelvic and presacral lymph nodes above the 
S3 segment, which allowed some sparing of posterior rectal wall distal to this level. 
Large treated volume was obtained since the average variation of prostate position relative 
to bony markers was approximately 8 mm in the superior and posterior positions, 7 mm in 
the inferior, 5 mm in the lateral and 4 mm in anterior position. The seminal vesicles are 
located high in the pelvis, and posterior to the bladder, which was very critical when 
reducing treated volume in T3 patients. 
When indicated, the periaortic lymph nodes could be treated through extended AP/PA 
portals or separate periaortic fields placed above the pelvic fields. The superior margin of 
the periaortic field was at the Th12-L1 vertebral interspace with the width usually above 10 
cm (determined by lymphangiogram or CT scan). (Chao et al., 2002, Dobbs et al., 1999) 
Conventional external-beam radiotherapy required daily radiation delivery to target 
volume using high-energy beams (more than 10MV). In most institutions a standard 
fractionation was used with 1.8 to 2Gy per day. In radical approach, initially a dose of 45-
50Gy was applied to the whole pelvis or to the prostate through two parallel opposed 
fields (AP/PA). Than addition of a boost dose was delivered, up to a total dose of 65-66Gy 
through lateral opposed fields, two anterior or two posterior oblique fields. (Chao et al., 
2002, Dobbs et al., 1999) 
2.2 Two-dimensional radiotherapy (2D-RT) 
Once a decision is being made to treat prostate cancer with external-beam radiotherapy, the 
radiotherapy plan is defined either to limit treatment to the gland or to extend treatment 
field to include the periprostatic tissues, seminal vesicles and pelvic lymph nodes. (Hayden 
et al. 2010) CT or MRI of the abdomen and pelvis is used to assess the involvement of 
surrounding structures. MRI is particularly useful for distinguishing capsular invasion, 
seminal vesicle involvement and periapical extension. CT scanning for treatment planning is 
performed to every patient, which means that two-dimensional (2D) radiotherapy is a step 
forward comparing to conventional radiotherapy. 
The patient is immobilized in supine position with skin tattoos over the pubic symphisis 
and laterally over the iliac crests to prevent lateral rotation. CT scans of pelvis are 
obtained with slice thickness of 4-5 mm. No oral, rectal or intravenous contrast is used. 
The CT section at the centre of the volume is used as the main planning slice to outline 
patient contour, target volume, rectum, and bladder. The margins of the target volume are 
determined by the tumor extent. The gross tumor volume contains entire prostate gland, 
but if there is a risk of seminal vesicles involvement, they must be included in target 
volume too. The gross tumor volume is outlined on the central slice only. To allow 
position variation, an additional margin is added to gross tumor volume (1-1.5 cm in all 
directions) defining planning target volume (PTV). For two-dimensional planning, PTV is 
outlined on multiple sections to ensure that the entire tumor is encompassed. The rectal 
outline must be transposed on to the central section so that the dose can be adequately 
calculated. Shaping the target volume by shielding blocks or multileaf collimators reduces 
the dose to normal tissues. 
Treatment technique depends on the target volume size and shape. Three-field technique 
using an anterior and two posterior oblique or opposed lateral fields give a high dose to the 
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prostate but spare the posterior rectal wall. Four-field (box) technique may result in better 
dose distribution when seminal vesicles are included in target volume, but increases the 
dose posteriorly. 
The patient is than treated daily, 1.8 to 2Gy per fraction, on linear accelerator. The correct 
position is assured with skin tattoos. The field centre is marked with a tattoo also. All fields 
are treated isocentrically with shielding as instructed. The recommended dose is 64Gy in 32 
fractions given in 6.5 to 7 weeks. (Dobbs et al., 1999) 
2.3 Three-dimensional conformal radiotherapy (3D-CRT) 
Introducing CT-based radiotherapy simulations by the mid 1980s and multileaf collimator 
in new aged linear accelerators, it became possible to arrange treatment fields to 
individually match prostate target volume minimizing high dose exposure to adjacent 
normal tissues. This led to dose escalation without inducing more toxicity and 
implementing three-dimensional conformal radiotherapy in clinical practice as a gold 
standard in prostate cancer radiotherapy treatment. Practically, the aim is to minimize 
treatment toxicity for patients with more favorable disease, and to maximize locoregional 
tumor control for those with less favorable disease. (Hayden et al., 2010, Dearnaley, 2001, 
Gazdda et al., 1996/97) 
For 3D-CRT treatment planning a multi-slice CT scan and 3D planning system is used. In 
order to minimize random and systemic setup error, prior to CT scan, patient should be 
positioned and immobilized in a fashion that position obtained can be maintained and 
reproduced. This is secured by the use of alpha cradles, shells or by positioning the patient 
in supine position with leg restraints. In all this cases a midline and lateral laser lights are 
used for set up. These markers are tattooed on the skin over the pubic symphisis and 
laterally over the iliac crests. This is very important for daily positioning of the patient and 
prevention of lateral rotation. The position is later verified by portal image. (Dobbs et al., 
1999, Hayden et al., 2010, Malone et al., 2000) 
CT scan of pelvis is performed in a treatment position. Patient should empty the rectum 
and the bladder should be comfortably full both on the simulation and on the radiation. 
This standard should be followed because the variation in bladder and rectum distension 
results in significant prostate displacement. A great controversy still remains regarding 
prostate apex. MRI of pelvis and CT/MRI fusion is recommended to reduce inter-
observer variability in contouring, improving target delineation accuracy, particularly the 
prostate apex. This fusion is also recommended were significant CT artifact is present i.e. 
from hip prosthesis. 
Once the CT and/or MRI scans are obtained on each slice a target volume and organs at risk 
are delineated. Organs at risk are adjacent structures endangered by high radiation dose 
delivered to treated volume. These organs include bladder, rectum, femoral heads and small 
bowel when it is in the treatment field. (Fiorino et al., 2009) 
In 3D-CRT of prostate cancer target volume consists of clinical target volume (CTV) and 
planning target volume (PTV). CTV includes prostate only, or prostate with seminal vesicles 
and lymph nodes depending on risk category of the disease. In low-risk prostate cancer, the 
risk of seminal vesicles involvement is less than 5%, so the CTV should be restricted to prostate 
only. But, for intermediate risk patients the risk of seminal vesicle involvement is higher (over 
15%) hence the proximal third of the seminal vesicles (1 cm) should be included in CTV. For 
high-risk patients proximal 2 cm of seminal vesicles should be in encompassed with CTV. In 
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cases were seminal vesicle involvement is proven, whole of them should be included in CTV. 
Any extracapsular extension is also delineated under the CTV, and even a margin of 2-5 mm 
(excluding rectum) should be considered in high–risk and T3 disease. (Hayden et al., 2010, 
Koh et al., 2003, Boehmer et al., 2006) According to RTOG guidelines in 2009, pelvic lymph 
node irradiation may be considered in high-risk patients judged by the treating clinician. The 
risk of lymph node involvement approaches the risk of distant metastases so the benefit of 
lymph node irradiation remains controversial.  (Lawton et al., 2009) 
PTV is a margin added to CTV to reduce the impact of set-up error and organ motion on 
CTV displacement. PTV also covers inter-observer variability in both delineating of 
mentioned structures and verification process. According to RTOG recommendation, a 
PTV is determined by institutional set-up and verification protocol, and measurement of 
institutional random and systemic errors of prostate position. (Lawton et al., 2009) In 
many institutions the acceptable CTV-PTV margin ranges from 5 do 10 mm. (Hayden et 
al., 2010) (Figure 2.) 
 
 
   
(a)     (b) 
 
   
(c)     (d) 
 
Fig. 2. Delineation of target volume (prostate-pink and seminal vesicles-purple) and organs 
at risk (bladder-green, rectum-red and femoral heads-light green and dark green) 
delineation. PTV margin-magenta (a, b, c). Sagital reconstruction (d). (With thanks to the 
Institute for oncology and radiology of Serbia, Belgrade) 
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When the delineation process is completed, the medical physicists arrange beam angles and 
adjust them to maximize target coverage and minimize high-dose exposure to normal 
organs. (Choe & Liauw, 2010) (Figure 3.) 
 
 
 
 
 
 
Fig. 3. Field arrangement for four-field (box) treatment (With thanks to the Institute for 
oncology and radiology of Serbia, Belgrade) 
Digitally reconstructed radiograph (DRR) is created by computer program transforming the 
CT slices into a radiograph image. DRR represents the referent image to which the later 
portal films of treatment field position are compared. (Figure 4.) 
Dose-volume-histogram (DVH) is also created and it shows the percent of prescribed dose 
to every delineated structure. For organs at risk the ALARA principle (as low as reasonably 
achievable) is recommended following the tolerant dose of each organ. But, although DVH 
gives valuable information on the dose to each structure, it is calculated on a single 
pretreatment pelvic organs position, and they are mobile. That is the reliability on a single 
pretreatment DVH is limited, and does not have to correlate with late toxicity (Fiorino et al., 
2009) (Figure 5.) 
www.intechopen.com
 Radiotherapy in Prostate Cancer 
 
175 
    
(a)     (b) 
Fig. 4. Digitaly reconstructed radiographs (DRR) for AP (a) and right lateral (b) field (With 
thanks to the Institute for oncology and radiology of Serbia, Belgrade) 
 
 
Fig. 5. Dose-volume-histogram (DVH) showing the doses delivered to each delineated 
structure (With thanks to the Institute for oncology and radiology of Serbia, Belgrade) 
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According to EAU guidelines in prostate cancer in 2010, for external radiotherapy, a dose of 
at least 74Gy to PTV is recommended for low-risk prostate cancer because the biochemical 
disease-free survival is significantly higher when compared to a dose of under 72Gy (69% 
vs. 63%; P=0.046). For intermediate-risk prostate cancer the dose is ranging from 76Gy to 
81Gy, and for high-risk prostate cancer a combination with androgen deprivation is 
recommended regardless dose escalation since the risk of systemic relapse has to be 
covered. (Heidenereich et al., 2011) 
The patient is treated daily, 1.8 to 2Gy per fraction, on linear accelerator in a position that 
matches the position taken during CT simulation. The correct position is obtained by 
immobilizing devices and by setting up the skin tattoo markers to treatment room wall 
lasers. Once the radiotherapy has started, portal films of arranged fields are taken on the 
accelerator, in treatment position and compared with digitally reconstructed radiograph 
(DRR) for set-up or other errors several times during radiotherapy course. 
2.4 Intensity-modulated radiotherapy (IMRT) 
Intensity-modulated radiotherapy is considered a grate improvement in radiation oncology. 
It is a form of 3D-CRT in which the optimization of the dose prescribed to the target volume 
is achieved by x-ray beam intensity changes. By using computer algorithms the intensity of 
the beam is changed in order to increase the dose difference between the target volume and 
organs at risk. 
Radiotherapy treatment planning using IMRT is based on a CT slices on which the 
physician delineates target volumes as for the 3D-CRT, as well as organs at risk. For each 
delineated structure the tolerant dose in imputed in the mathematical algorithms and than 
the beam intensity is calculated as a function of beam angle. The beam angle is individually 
adjusted by inclination of the radiotherapy bed, collimator or gentry. (Valicenti et al., 2000) 
Unlike 3D-CRT, in IMRT the dose from each beam is not delivered all at once. At each beam 
angle, the intensity of the beam is modulated by multiple smaller subfields that change in 
time. This allows a high degree of dose conformity around complex and irregularly shaped 
tumors (Choe & Liauw, 2010) and dose escalation up to 86Gy. (Zelefsky et al., 2002) 
2.5 Organ motion tracking and image-guided radiotherapy (IGRT) 
Highly conformal radiation therapy requires precise localization of the prostate. Since the 
prostate gland is a movable organ due to breathing and distention of rectum and bladder, a 
variety of strategies have been developed to account prostate motion including 
transabdominal ultrasound-based imaging, on-line CT and implantation of radiopaque 
markers. 
The prostate gland can not be visualized on portal images, but radiopaque fiducial markers 
can be placed within the prostate. These markers can be visualized on portal imaging so 
prior to every treatment a correction of targeting can be made. (Choe & Liauw, 2010) A 
minimum of three markers should be implanted under ultrasound guidance in the 
ipsilateral apex, base and contra-lateral mid-gland one week prior to simulation. (Hayden et 
al., 2010) This technique is used to track interfraction movement (prostate movement 
between treatments), but it cannot account prostate movement during treatment 
(intrafractional movement). Nowadays there is a growing interest in real-time tracking of 
the prostate. There is a special system that uses a real-time tracking of the radiofrequency 
transponders implanted into the prostate and if they present outside of the predetermined 
margins the radiation stops.  
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These new technologies are still under investigation, but first results are optimistic. (Choe & 
Liauw, 2010) When IGRT is used prostate displacement caused by rectal distension is 
largely corrected. (Hayden et al., 2010) 
2.6 Acute and late toxicity of external-beam radiotherapy in prostate cancer 
Radiation-induced complications can be acute and late. Acute adverse events occur during 
treatment and late may develop months to years after treatment. When we irradiate the 
prostate, acute and late toxicity are a consequence of high dose given to the surrounding 
organs i.e. bladder, rectum and skin. The severance of these side-effects largely depends on 
the tissue volume irradiated and relates to the treatment technique. 
During conventional radiotherapy of the prostate acute toxicity include acute proctitis 
followed by rectal discomfort, tenesmus and diarrhea, and rarely rectal bleeding. It is 
mostly mild and resolves after symptomatic therapy with hydration and antidiarrheal and 
anti-inflammatory medication. Skin reactions include erythema, dry and humid 
desquamation. According to RTOG scale (RTOG, 1999) acute toxicity has four grades of 
severity stated in table 1. 
 
Grade 0 1 2 3 4 
Dermatitis 
No 
complications 
Mild erythema 
or dry 
desquamation 
Moderate 
erytherma or 
incipient moist 
desquamation, 
mild skid 
edema 
Confluent 
moist 
desquamation 
more than 1.5 
cm of the skin, 
moderate 
edema 
Ulcerations or 
skin necrosis 
Colitis 
No 
complications 
Asymptomatic 
Abdominal 
pain, mucus 
and/or blood 
in stool 
Abdominal 
pain, fever, 
peritoneal 
signs or ileus 
Perforation 
Diarrhea 
No 
complications 
Up to 4 stools 
per day 
4-6 stools per 
day, night 
stools 
More than 7 
stools per day 
and/or 
incontinency 
or parentheral 
substitution 
due to 
dehydrations 
Hemodynamic 
collapse 
Cystitis, 
dysuria 
No 
complications 
Mild dysuria 
Moderate 
dysuria that 
need 
symptomatic 
therapy 
Symptoms not 
relieved on 
symptomatic 
therapy 
 
Table 1. Acute toxicity in radical radiotherapy of prostate cancer-RTOG scale 
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The most frequent adverse event on the urinary tract is radiation cystitis producing dysuria, 
nocturia, frequency and urgency. It is low graded in most cases (7.7%) while severe urinary 
complications are seen in less than 0.5% of patients. According to RTOG study on over 1000 
prostate cancer patients treated with external-beam radiotherapy, acute toxicity occurs in 70-
90% of the patients with mild symptoms. Moderate symptoms are developed in 20-45% of 
the patients while 1-4% has severe or prolonged reactions. (Dearnaley, 2001) 
Although acute toxicity is very unpleasant for the patient it usually resolves after the 
treatment. Late toxicity is of much more concern since it is unpredictable and very often 
irreversible. According to RTOG, late toxicity also has four grades of severity (table 2). 
Mostly it is mild and does not influence quality of life, but sever late toxicity is reported in 4-
8% of patients. Most common genitourinary side effects are chronic cystitis (5%), 
incontinency, urethral stricture (5%, mostly patients with previous transurethral resection of 
the prostate), bladder ulceration and impotency (30-40%). Late toxicity on rectum affects 3% 
of the patients and includes tenesmus, sphincter dysfunction, occasional bleeding, strictures 
or ulcerations. (Dearnaley, 2001) 
 
 
Grade 0 1 2 3 4 
Bladder 
No 
complications 
Mild epithelia 
atrophy, 
discreet 
teleangiectasia 
Diffuse 
teleangiectasia, 
macroscopic 
hemathuria 
Frequent 
urinating, 
dysuria and 
hemathuria, 
bladder capacity 
less than 150 ml 
Bladder 
necrosis, 
capacity less 
than 100 ml, 
hemorrhagic 
cystitis 
Skin 
No 
complications 
Mild skin 
atrophy, 
hyperpigment
ation, hair loss 
Moderate skin 
atrophy, 
teleangiectasis, 
total hair loss 
Severe skin 
atrophy, severe 
teleangiectasia 
Ulceration 
Bowels 
No 
complications 
Mild diarrhea 
or increased 
bowel motion, 
or mild rectal 
bleeding 
Moderate 
diarrhea, 
abdominal pain, 
rectal mucus or 
harder bleeding 
Ileus or bleeding 
that requires 
surgical 
treatment 
Necrosis, 
perforation, 
fistula 
Table 2. Late toxicity in radical radiotherapy of prostate cancer-RTOG scale 
Introducing 3D-CRT and IMRT the volume of bladder and rectum irradiated is limited, but 
the dose escalation can still induce significant toxicity. In trials of dose escalation, reported 
rates of acute toxicity are very similar to those of conventional radiotherapy. Late toxicity 
however is still considered high. MD Anderson trial has shown a significant gastrointestinal 
toxicity (grade 2 or more) in 25% of patients with escalated dose comparing to 13% in low 
dose group (78Gy vs. 70Gy). (Kuban et al., 2008) The Dutch trial reported 26% of late rectal 
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toxicity grade 2, and Medical research council 33% in dose escalated group. (Al-Mamgani et 
al., 2008, Dearnaley et al., 2007) These results compare with reports of IMRT treatment with 
81Gy (3% of patients experienced late rectal toxicity at grade 2 or grater) and treatment with 
IGRT with 79.8Gy (12% of patients with grade 2 rectal toxicity). (Hayden et al. 2010) For 
urinary toxicity none of these trials found significant correlation between late adverse events 
and radiation dose. Although improved radiotherapy techniques appear to enable dose 
escalation with less toxicity, the optimal dose that can eradicate the disease without the risk 
of toxicity is jet to be defined. (Choe & Liauw, 2010) 
2.7 Results of external-beam radiotherapy of prostate cancer 
Following external-beam radiotherapy, long-term clinically assessed local tumor control is 
good for patients with stage T1 cancers (83% at 15 years), but it is falling to 65-68% for T2 
and 44-75% for T3 cancers. Reported incidence of positive biopsy after external-beam 
radiotherapy vary from 18 to 45% and increases with disease bulk from 15% for T1 disease, 
to 68-79% for men with T2 and T3 cancers. Regarding biochemical control, Hanks et al. 
reported a long-term biochemical control in 72% of T1 cancers, falling to 22% and 28% for 
bulky T2 and T3 cancers in a mean follow-up of 12.6 years. 
PSA level and Gleason score are powerful predictors of outcome. In patients with low 
Gleason score the rate of biochemical control ranges about 75%,  compared to only 18% for 
Gleason score 7 and 0% for Gleason score 8 or 9. In patients with pretreatment PSA more 
than 20 ng/ml only 28% remained biochemically free of progression at 4 years in the results 
of Hanks et al (Dearnaley, 2001) 
Several randomized controlled trials and one meta-analysis shown that improved 
biochemical outcomes (biochemical failure free survival) are associated with dose escalation. 
(Kuban et al., 2008, Al-Mmgani et al., 2008, Dearnaley et al., 2007, Zietman et al., 2010, Viani 
et al., 2009). Radiation Therapy Oncology Group trials have even shown that higher 
radiation dose improves disease-specific and overall survival in high-grade prostate 
cancer. (Valicenti et al., 2000) Despite promising results of dose escalation there are still 
uncertainties regarding routine application of dose escalation especially. The subgroup of 
patients that will benefit the most from dose escalation is not clearly defined. These trials 
enrolled men in all risk groups of localized prostate. Only U.K. Medical Research Council 
trial divided patients in risk groups showing the benefit of dose escalation in all groups. 
But statistically significance was reached only in high-risk group. In the Dutch trial the 
benefit from dose escalation from 68 to 78Gy was also registered in intermediate and 
high-risk patients. These results led to a question whether a higher dose is required for 
low-risk prostate cancer. Although MD Anderson trial shown the benefit form dose 
escalation in high-risk group of patients, it also reported longer follow-up of 8.7 years that 
can indirectly demonstrate a benefit of dose escalation even in the low-risk group. While 
the improved biochemical outcomes are practically proven with dose escalation, there is 
still no sufficient evidence of improvement in cancer-specific survival and overall 
survival. (Choe & Liauw, 2010) 
Regarding overall survival, radiotherapy is efficient method for many cases of localized 
prostate cancer. Five-year overall survival for T1 and T2 stage ranges about 70-80%, and 90% 
of local tumor control. Locally advanced stages have poorer prognosis with 5-year overall 
survival of 40-50%. High Gleason score is the most significant negative prognostic marker 
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since it is associated with higher malignant potential. Cancer related death for high Gleason 
score tumors (8-10) is about 60-80% in 15 years. (Hadzi-Djokic, 2005) 
3. Brachytherapy in prostate cancer 
In the age of the developed imaging technology (CT, MRI, PET, US), and advanced 
biochemical markers (tumor-specific and nonspecific), a large number of tumors, including 
prostate cancer, are being diagnosed in the early stages. In early stages of prostate cancer 
(T1-T2 N0 M0, PSA <10ng/ml, Gleason Score <6, prostate volume <50ml, maximum urinary 
flow>15ml/s), in addition to the conventional, laser and robotic prostatectomy, 
hyperthermia, hormone therapy and brachytherapy is often applied. 
In brachytherapy sealed sources of radiation are placed either in direct contact or in 
proximity of the tumor, so the interstitial brachytherapy for localized prostate cancer often 
represents the method of choice, and its efficiency is not far behind the effectiveness of 
surgery, with less morbidity. Brachytherapy allows local application of extremely high 
doses (up to 160Gy, even more). The effectiveness of prostate cancer brachytherapy is 
directly correlated with the total dose and precision of administration, which represents its 
advantage over transcutaneous radiotherapy. 
Prostate cancer is usually multicentric, so the brachytherapy target is the entire prostate, and 
the total dose has to cover the area of about 2-5 mm beyond the prostate capsule. From the 
point of radiotherapy, particularly brachytherapy, the initial prostate cancer (prostate itself, 
with or without vesicles involved) represents the ideal target, with adequate spare of the 
urethra, rectum, bladder and perineal area. Moreover, brachytherapy can be applied within 
a combined radiotherapy (brachytherapy + transcutaneous radiotherapy) by the additional 
dose (boost), as well as in the case of local recurrence or rest after prostatectomy or 
transcutaneous radiotherapy. 
Brachytherapy for prostate cancer is not a new therapy method, though in the history of 
medicine it experienced its ups and downs, mainly due to the previous imperfections of 
visualization techniques and applications, as well as, imperfection in radiation and 
dosimetric characteristics of the radiation sources, while today it is a routine method of 
treatment. With the introduction of transrectal ultrasound (TRUS), CT and development of 
new sources of radiation (103Pd, and 192Ir), techniques of radioisotope implantation (loading 
and afterloading) and computer systems for brachytherapy planning in routine clinical 
practice, interstitial brachytherapy for prostate cancer began to experience another upswing, 
but with markedly better results and lower morbidity. 
Today, two modalities for interstitial brachytherapy are applied: 
1. low dose rate (LDR), about 2Gy/day, with low activity 125I sources (from 0.03 to 1.5GBq 
per seed, max. photon energy of 35.5 keV, the half-life about 60 days in the form of 
cylinders /height 4.5 mm, 0.8 mm diameter, encapsuled in titanium sleeve/) or 103Pd 
(Blasko et al., 2000) (dose rate to about 5Gy/day; activity around 0.07GBq per source, 
the maximum photon energy of 21 keV, the half-life 17 days in the form of cylinder/ 
height 4.5 mm, 0.8 mm diameter /or spheres/ diameter of about 1 mm /) – a 
permanent implant; 
2. (high) dose rate (HDR) about 0.2 to 3Gy / min with radioactive 192Ir source in the form 
of cylinder /dimensions around 0.6 x3,5 mm / (initial activity of about 370GBq; time 
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half-life of 74.2 days, mean photon energy of about 380keV,) - a temporary 
implantation. 
3.1 Low dose rate brachytherapy 
Strictly speaking, from the point of view of radiobiology, the only differences (not great) in 
the indications for applying permanent (LDR) or temporary implantation (HDR) are mostly 
related to tumor grade. For example, with  low-grade and low-risk tumors (eg Stage<T2a, 
PSA<10, Gleason Score 2-4) and slow-growing tumors, we expect greater efficiency in the 
application of permanent implants, while with tumors of high grade and higher risk, higher 
efficiency is expected from temporary implantation. Although there are relative differences 
in the indications for application of LDR or HDR brachytherapy, it seems that the 
predominant technique is the one with permanent implants (LDR). Selection of isotopes (125I 
or 103Pd) is in the favor of the cheaper iodine, so if otherwise not indicated it's considered 
that radioisotope 125I is being used in LDR brachytherapy for treating prostate cancer. 
Permanent implants are rarely used in cases of rest or local recurrence after prostatectomy 
or transcutaneous radiotherapy. In this case a HDR brachytherapy with 192Ir of initial 
activity over 370 GBq, by using afterloading device, is applied. 
Prostate brachytherapy requires a multidisciplinary approach, which assumes collaboration 
between urologists, radiation oncologists (brachytherapists), anesthesiologists and 
brachytherapy physicists. Regardless of which brachytherapy modality is implemented in 
prostate brachytherapy, and with the aim to providing a top quality treatment, all steps are 
strictly determined: 
1. Assessing the stage and spread of the disease (laboratory-biochemical, prostate 
morphology / palpatory findings, prostate size - US and TRUS /, histopathological 
verification and determination of Gleason Score, a CT/MRI, scintigraphy, 
determination of TNM disease stage) 
2. Assessing the possibility of applications (talk with the patient, the patient’s state, 
maximum urinary flow rate, the presence of residual urine, previous TUR, assessment 
of cardiovascular conditions, the possibility of implanting, anatomy of the pelvis, 
prostate size, type of implant LDR vs. HDR) 
3. Preparing the patient prior to implantation - 24 hours in advance (admission of the 
patient, medical therapy, anti-coagulant and antibiotic, preparation of the patient, 
rectum cleaning) 
4. Preparation of instrumentarium (selection and sterilization of instruments, calibration 
of stepper, network and TRUS ) (Figure 6.) 
5. Patient’s positioning and anesthesia (in lithotomic position on the movable therapy 
table; spinal or general anesthesia) 
6. Placing markers of critical radiosensitive structures (Folly catheter for marking the 
bladder and urethra) 
7. Setting TRUS probes, template and steper, and prostate visualisation, and visualisation 
of urethra and rectum (in steps of max. 5 mm from base to apex (Grey et al., 2000), 
(Figure 7. a, c)  
8. Pre-planning (determinatuion of the number and location of radiation sources and 
methods of implantation) 
9. The application (placing the radiation source guides/needles; in the LDR technique 
inserting a radiation source - seeds) - TRUS-guided (Figure 8. b) 
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10. Verification and correction (cistoscopic, fluoroscopic, x-ray (Figure 7. c) - optional CT 
and/or MRI; in case of LDR brachytherapy adding of seeds, if necessary) 
11. Computer reconstruction (seeds / LDR / - needles / HDR /, prostate capsule, the 
position of the urethra and rectum), optimization, plan analysis (the determination of 
DVH - Dose Volume Histogram, ie. minimum volume of prostate receiving 90%, 100%, 
150% and 200% of the total dose, and the dose and volumes that receive critical 
radiosensitive structures), (Figure 7. d, e); 
12. Irradiation; for HDR brachytherapy: deapplication of needles or observation of the 
patient (LDR) 
13. Transport of patient to the patient room 
14. Patient care (analgesic and antibiotics therapy, toilet) 
15. Check-up (of dysuric problems and estimate the degree of proctitis) and discussion 
with the patient, the patient's discharge 
16. Regular checks (during treatment /HDR/ and in 2, 3, 6, 12 and 18 months, then 
annually - the level of PSA, rectal examination, assessing the level of dysuric problems 
and evaluation of potency) 
 
 
 
 
 
Fig. 6. Schematic representation of TRUS-guided brachytherapy with radioactive seeds. 
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(a)      (b)      (c)  
 
  
(d)    (e) 
(a) TRUS guided needles application 
(b) Administrated needles /guides of 192Ir source  
(c) Radiographic verification of the needles’ positions 
(d) Isodose transversal view 
(e) 3D treatment volume  
(With the thanks of the General Hospital Medical System, Belgrade) 
Fig. 7. Steps in HDR prostate cancer brachytherapy - real patient  
When using permanent implantation (monotherapy) radiation sources (seeds) remain in the 
prostate of the patient. It is therefore recommended to the patient a minimal two-week 
sexual abstinence and avoidance of contact with pregnant women and small children for a 
minimum of 2 months. A typical therapeutic dose of radiation, when 125I is implanted, is in 
the range 140-160Gy, and when 103Pd is implanted to about 125Gy. In a case of a "boost" 
dose, for 125I a somewhat lower dose of 80-120 is applied or to about 90-100Gy for 103Pd. 
(Blasko et al., 2000, Beyer, 2001) 
3.1.1 Results of low dose rate brachytherapy 
Prostate cancer with its characteristics and different biological behavior represents a 
problem in the analysis of brachytherapy final outcomes in terms of overall survival or local 
control. We are aware that many patients with untreated prostate cancer can survive tens of 
years, ie. do not die from prostate cancer. Therefore to evaluate the effectiveness of 
treatment of patients with prostate cancer, as for overall survival and local control, the PSA 
level was adopted. 
Greem and associates (Greem et al., 1997 )provide representation of the results of treatment 
of patients with permanent implants (monotherapy), showing a five-year survival of NED 
(no evidence of disease) of 94%, 84% and 54% for low risk, medium risk and higher risk 
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group of 403 patients, respectively . Blasko and associates (Blasko et al, 2000) show the 
results of a five-year biochemical PSA control: 94%, 82% and 65% for low risk, medium risk 
and higher risk respectively. Slightly worse, but comparable results are displayed by other 
authors: 85-94%, 33-82% and 5-65% for low risk, medium risk and high-risk group, 
respectively (Beyer, 2001). Based on these results, most urologists and brachytherapists 
exclude a group of patients at high risk from the LDR brachytherapy and consider them 
patients with advanced disease in which the tumor penetrated the prostate capsule. 
Association of American Brachytherapy Society has established a Low Dose-Rate Task 
Group (Merrick, G., Zelefsky, M., Sylvester, E., Nag, S., Bice, W) with the task of defining the 
general criteria for inclusion of patients with prostate cancer in the group for the treatment 
by permanent implants (LDR): expected survival > 5 years, clinical stage T1b-T2c and 
selected T3, Gleason Score<10, PSA<50ng/ml, without involved lymph nodes, no distant 
metastases, Karnofsky performance status> 70%. Criteria for exclusion are: inflammatory 
prostate disease, severe urinary obstruction, the middle lobe hyperplasia, extensive TUR 
defects, a prostate size greater than 60x50 mm, the extension of disease to the seminal 
vesicles and bladder, involved lymph nodes, previously conducted EBRT. Absolute 
contraindications are distant metastatic disease, the inability of anesthesia (general, spinal, 
epidural), no possibility of peaceful lying, expected survival <5 years. 
It is obvious that the consistent application of these criteria for inclusion and exclusion 
would ensure consistent application of LDR brachytherapy in this roup of patients, with the 
results of treatment (five-and even ten-year PSA control NED> 85%). 
3.1.2 Toxicity of low dose rate brachtherapy 
Mild and transient acute urinary symptoms (LENT SOMA, 1995) (hematuria and dysuria 
grade G1-G2) often accompany LDR brachytherapy, while the acute symptoms on the rectum 
(proctitis, tenesms and bleeding) are rare and mainly a result of edema and hematoma. All of 
the symptoms can be associated to radiation or trauma during the application procedure. 
As late symptoms of bladder neck irradiation, chronic irritative urinary symptoms may occur 
and in a small number of cases due to urethral scarring, obstruction or incontinence may 
occur. Late effects on the rectum are mild, and manifested by periodic bleeding and 
proctitis. Erectile function was preserved for over 70% of treated patients whose erectile 
function was satisfactory before the implementation of brachytherapy. In order to preserve 
erectile function, it is important to avoid positioning of seeds in the perineal area, outside 
the prostate apex, which prevents the occurrence of fibrosis and consequent 
devascuralisation of this region. Most patients (over 2/3) treated with permanent implants, 
estimate their quality of life as good, which is just as important as biochemical and clinical 
course of disease. 
However, due to the relatively limited fixation of radioactive seeds (which are smooth on 
the surface) there is a possibility of their inter-prostate migration and the creation of "hot" 
and "cold" zones, as well as, their migration to other organs (rectum, bladder and pelvic 
veins and even lungs), which sometimes requires serious surgical treatment and drastically 
reduces the quality of patient's life. 
3.2 High dose rate brachytherapy 
HDR temporary prostate cancer brachytherapy with 192Ir entered into clinical practice 
mainly in combination with transcutaneous radiotherapy about 20 years ago. Obviously, it 
was necessary to acquire certain technical and technological advances for its application 
www.intechopen.com
 Radiotherapy in Prostate Cancer 
 
185 
Soon, the advantages of HDR regime compared to LDR brachytherapy of prostate cancer 
were noticed, which are reflected in: the high precision of application, the possibility of 
subsequent dose optimization, more accurate dose planning and application, sparing the 
surrounding tissues and organs, more favorable radiobiological effect, the fact that after 
treatment there are no sources of radiation in the patient and therefore no possibility of 
source "seeds" migration into the bladder, rectum or surrounding larger blood vessels, there 
is no irradiation of staff, there is the possibility of extending indicational scope of 
application and easier possibility of combination with transcutaneous radiotherapy. 
However, when it comes to temporary HDR brachytherapy of prostate cancer as 
monotherapy, less obvious results and experiences are presented in the literature, so one can 
get the wrong impression that this modality of brachytherapy is either less efficient or at 
very least, least mystified. To clarify this problem to an extent, if not totally resolve, the 
association of American Brachytherapy Society has formed a High-Dose Rate Task Group 
(Hsu, C., Yamada, Y., Vigneaut, E., Pouliout, J.) with the aim to define general criteria for 
inclusion of patients with prostate cancer in the treatment group Temporary implants 
(HDR), which was formed following the general criteria for inclusion: clinical stageT1-T3 
and selected T4, Gleason Score any, PSA no upper limit, no distant metastases (T1-3N0M0).  
Criteria for relative exclusion are: severe urinary obstruction, extensive TUR defects, the 
TUR within 6 months, vascular disease. Absolute contraindications are impossibility to 
anesthesia and no possibility of peaceful lying  
Given all the above-mentioned recommendations, for inclusion and exclusion, and in 
particular those given by the American Brachytherapy Society, extended operational criteria 
and opinions can be formed related to the application of HDR brachytherapy in different 
patient groups, including recommendations on the total dose and method of its fractions, 
and as: 
 monotherapy - with tumor stage T1-T2 N0 M0, Gleason Score <7 and prostate volume 
to 70 cc and T3 confined to the prostate (TD - 31.5 Gy/3 fr. To TD45/6 hypofractioned 
(Duchesne & Peters, 1999) or hyperfractioned / pause between the fraction of at least 6 
hours or even up to 54Gy/9 fr./5 days (Yoshioka et al., 2006) (where the stage T3 N0 
M0 may include seminal vessicles); 
 boost in the combined radiotherapy approach (TD - 12 (Mate et al., 1998) -24 (Demanes 
et al., 2009) Gy/1-4 fr. EBRT ± 36-50Gy or 9-15Gy/1-2 fr. EBRT ± 65Gy ); 
 for recurrent disease confined to the prostate (depending on the previousl therapy TD> 
Gy/1-2 7-14 fr. to 8Gy/4 fr.) 
 further: to have no contraindications (no indication for exclusion). 
3.2.1 Results of high dose rate brachytherapy 
Yoshioka et al (Yoshioka et al., 2006) presented the results of 111 patients (15 low, 28 
medium and 68 high risk, according to the ASTRO criteria (ASTRO, 1997) treated with 
HDR temporary implantation (monotherapy), showing a three-year and five-year survival 
without signs of biochemical disease of 83% and 70%, and overall survival of 100% and 
97%, respectively. For the 17 patients from high risk groups, in which biochemical relapse 
was observed, in 9 patients the presence of distant metastases were confirmed, of which 4 
patients died. Given that this group of patients is not stratified based on risk, it is clear 
that the shown results after the HDR brachytherapy are comparable or even better than in 
patients treated with permanent implants (monotherapy) (Blasko et al., 2000, Beyer, 2001, 
Greem et al., 1997). 
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3.2.2 Toxicity of high dose rate brachytherapy 
Mild and transient acute urinary symptoms (dysuria and hematuria of grade G1) followed 
HDR brachytherapy in about 50% of patients in the first week or two, and persist for up to 
6 months in less than 35% of treated patients, while grade G2 symptoms occurred in about 
11 % of patients in the first weeks after treatment and after 6 months they completely 
disappeared. Pronounced symptoms of grade G3 (urethral stricture at the level of bladder 
base) are very rare (less than 2%), and they require a retention of urinary catheter, and 
usually occur immediately after irradiation, and disappear within ten days. Acute 
symptoms of grade G1 rectum (proctitis, tenesma and bleeding) are rare and mainly are 
result of edema and hematoma, and occur in less than 25% of patients in the first weeks 
and decrease to about 8% in the 6-month after conducted therapy. Acute complications of 
grade G3 were not observed. 
All listed acute symptoms may be connected to radiation and trauma during application 
procedure, although problems have not been noted during the application itself. 
The frequency and severity of late complications after HDR brachytherapy is similar to the 
permanent implant brachytherapy (LDR), except that complications associated with the 
migration of radiation sources do not occur. 
When HDR brachytherapy (22-24 Gy/5-6 fr.) is applied in combination with transcutaneous 
radiotherapy (EBRT to 40Gy), the results of treatment (five-year survival 
NED/biochemical/and overall survival) of 63% in patients with high risk are comparable and 
slightly better than with the application of brachytherapy (LDR and HDR) as a monotherapy. 
(Deamens et al., 2009) In the same paper, the authors conclude that no benefit was noted when 
applying deprivate androgen therapy in relation to combined radiotherapy. 
Acute and late effects on the bladder and rectum are more pronounced in cases of combined 
radiotherapy, which can be expected. 
4. Postoperative radiotherapy in prostate cancer 
Radical prostatectomy is proven treatment modality for prostate cancer control for a long 
time. Some authors report 10-year cancer-specific survival of 85-90% in localized prostate 
cancer after radical prostatectomy, and 82% at 15 years. Survival is better if the tumor is low 
grade i.e. low Gleason score and low stage.  
The risk of surgical margins positivity is of great concern after radical prostatectomy. 
Positive margins are noticed in 28% of patients with T1-T2 prostate cancer and prostate apex 
is the most common site. For T3 cancers this percent is even higher-up to 52%.  
High tumor stage (T3a and T3b) and a positive surgical margin are strong predictors of local 
recurrence, biochemical and clinical failure. In general, it is considered that the percent of 
local recurrence after radical prostatectomy ranges about 15% for T2 prostate cancers, and 
50-70% for T3 tumors. 
In order to analyze the impact of predictive factors on development of local recurrence, 
univariate and multivariate analyzes were performed. In univariate analyzes strong 
predictors of local relapse are high-grade cancer, positive surgical margins and involvement 
of seminal vesicles. In multivariate analyzes these predictors are high-grade tumor, positive 
surgical margin and elevate prostatic phosphatase.  
Identification of patients that are candidates for adjuvant therapies after radical 
prostatectomy is still a great issue. The adequate treatment modality for these patients is an 
open question too. There is no consensus yet.  
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After radical prostatectomy, the application of radiotherapy can lower the incidence of local 
relapses, but its effect on distant metastases appearance is not confirmed. Alternative 
regimen is the use of androgen-deprivation therapy alone or in combination with 
radiotherapy which can also improve local control and eradication of distant metastases. 
(Hadzi-Djokic, 2005) 
Three randomized trials (Bolla, Wiegel & Thompson), have shown an advantage in 
biochemical relapse-free survival with postoperative radiotherapy for men with positive 
surgical margins or pT3 disease. These trials compared postoperative radiotherapy with 60-
Gy to the prostatic fossa to radical prostatectomy alone in men with high-risk prostate 
cancer. With the use of postoperative irradiation the 5-year biochemical progression-free 
survival was significantly improved, as well as clinical progression-free survival. 
Thompson’s trial has also show an advantage of overall survival (10.3 years for irradiated 
patients after prostatectomy to 3.1 year for prostatectomy only). Bolla failed to demonstrate 
this advantage. That means that not all men with adverse prognostic factors will relapse. 
Also, not all men treated with postoperative radiotherapy will be cured. Combined 
treatment is also associated with greater toxicity than radiotherapy or prostatectomy alone. 
So what will the optimal treatment be? (Hayden et al., 2010, Bolla et al., 2005, Wiegel et al., 
2009, Thompson et al., 2009) Eastham et al. managed to give actually 4 possible scenarios for 
post-prostatectomy setting: (1) there is no residual disease and adjuvant radiation is not 
necessary; (2) persistent disease is present in the prostatic fossa only and adjuvant 
irradiation may provide long-term cure; (3) there is a residual local disease as well as 
microscopic disseminated disease and adjuvant irradiation may eradicate local disease but 
will have no impact on the systemic component; (4) disease is only systemic and adjuvant 
local irradiation is not necessary.  
Salvage radiotherapy in the setting of a rising PSA after prostatectomy is unproven and still 
controversial. This is most likely the result of inadequately selected patients for post-
prostatectomy irradiation. Many of them already have systemic recurrence so a detail 
diagnostic workout is necessary. (Eastham et al., 2010)  
The special issue is the use of adjuvant hormone therapy. Some studies show that the 
application of adjuvant hormone therapy reduces the risk of positive surgical margins, 
improves local disease control, eradicates micro metastases and prolongs time to 
progression and overall survival. On the other hand, neoadjuvant hormone therapy, prior to 
surgery, in order to downstage the disease, has not been proven for successes neither in 
preventing biochemical or clinical relapse nor in improving survival so in most centres it is 
deserted. (Dearnaley, 2005) 
5. Androgen-derprivation therapy combined with radiotherapy of the prostate 
cancer 
Radiotherapy is traditionally the treatment of choice in locally advanced prostate cancer. 
Unfortunately the results of radical radiotherapy regarding 10-years and 15-years overall 
survivals are not satisfactory (Zlotecki, 2001) (Table 3.) 
Androgen deprivation therapy is used routinely in combination with radiotherapy for 
locally advanced prostate cancer, but recent studies show that it improves treatment result is 
localized and intermediate-risk disease.(Milecki et al., 2010). 
Hormone therapy, that is in fact androgen deprivation, can be realized in several ways: 
orchyectomy, blockade of the hypothalamus-hypophysis-gonade path (with gonadothropin 
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realizing hormone agonist) or by direct blockade of androgen receptors with androgen 
antagonists. (Anderson, 2003) Although, it is generally thought that androgen deprivation 
combined with radiotherapy influence the results of treatment in local and systemic way, it 
is uncertain whether that action is the result of radiosensitizing, systemic micro metastases 
eradication or both. Androgen deprivation leads to the shrinkage of the entire prostate 
gland reducing the irradiated volume to which the higher dose can be applied. In several 
studies this prostate shrinkage is ranging form 30% to 40%. Some authors say that it 
improves radiotherapy effectiveness by oxygenation of hypoxic cancer cells and that it even 
induces apoptosis and tumoricidal immune system response.  
 
 
Study/Institution Clinical T stage 
10 Year Survival 
(%) 
15 Year Survival 
(%) 
Pattern of Care T3-T4 33 23 
RTOG 75-06 T3-T4 38 No results 
Mallinckrodt T3 38 No results 
Stanford T3 35 18 
Stanford T4 15 15 
M.D. Anderson T3 45 31 
 
Table 3. 10 and 15-year survival rate for patients with locally advanced prostate cancer 
treated with radical RT 
The role of androgen deprivation therapy is unclear in men with low risk prostate cancer 
but some patients still received it as primary or neoadjuvant treatment. The Radiation 
Therapy Oncology Group (RTOG) 94-08 randomized trial included almost 2000 men with 
T1b-T2 prostate cancer and PSA less than 20ng/ml. Androgen deprivation therapy was 
administered 4 months prior or concomitantly with radiotherapy. Overall survival at 8 years 
was 76% vs. 73% for combined treatment and radiotherapy only, respectively. The disease-
specific survival was 98% for hormone and irradiation vs. 99% for radiotherapy alone. This 
study did not bring solid results, as well as many others, because some patients were 
clinically in a higher risk stage than deemed low risk according to National Comprehensive 
Network classification. Retrospective studies of Bolla et al. and Cietzki at al. are among few 
that have shown the advantage of radiotherapy combine with androgen-deprivation in low 
risk prostate cancer (Milecki et al., 2010)  
For intermediate and high-risk patients many randomized studies were performed such as 
RTOG 85-31 (977 patients T1-T2, T3, N+, adjuvant hormone therapy vs. radiotherapy alone), 
RTOG 86-10 (456 patients, T2-T4, neoadjuvant/concomitant hormone therapy for 4 months vs. 
radiotherapy alone), EORTC 22863 (415 patients, T1-T4 prostate cancer, concomitant/adjuvant 
hormone therapy for 36 months vs. radiotherapy alone). In 5-years follow-up all of them have 
shown a statistically significant difference in improved local disease control, reduction of 
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distant metastases and longer progression free survival in hormone therapy-radiotherapy 
group. (Jelić et al., 2005) (Table 4.) 
 
 
 N Stage Therapy 
Therapy 
duration 
Local 
control 
PFS (%) 
OS 
(%) 
Follow-up 
RTOG  
85-31 
977 
T1-T2, 
N+,T3 
Adj 
vs. 
only RT 
>24m vs. 0 + 
53 vs. 20 
p<0.0001 
Gs 8-10 
66 vs. 55 
p=0.03 
5 years 
RTOG  
86-10 
456 T2-T4 
Neoadj/conc 
vs. 
only RT 
4m vs. 0 + 
33 vs. 21 
p=0.004 
Gs 2-6 
70 vs. 52 
p=0.015 
5 years 
EORTC 
22863 
415 T1-T4 
conc/adj 
vs. 
only RT 
36m vs. 0 + 
85 vs. 48  
p<0.001 
79 vs. 62 
p=0.01 
5 years 
RTOG  
92-02 
1554 
T2c-
T4 
Neoadj/conc
/adj 
vs. 
Neoadj/conc 
28m vs. 0 + 
46.4 vs. 
28.1 
p<0.001 
Gs 8-10 
81 vs. 70.7 
p=0.044 
5 years 
RTOG  
94-13 
1323 
T1c-
T4 
Neoadj 
vs. 
adj 
4m vs. 4m + NA NA 4 years 
 
Table 4. Hormone therapy and RT. Randomized studies 
Bolla M. recommends concomitant and adjuvant hormone therapy for three years in 
combination with radiotherapy for patients with locally advanced, intermediate or high-risk 
prostate cancer. (Bolla, 2003) 
Although it is shown that androgen deprivation before, concomitantly and/or after 
radiotherapy significantly improves local disease control, minimizes progression and 
prolongs overall survival in locally advanced prostate cancer on intermediate and high-risk, 
there is not enough evidence for recommendation of optimal time to start hormone therapy, 
the type of hormones and the duration of the treatment which in clinical trials lasts from 3 
months to 3 years. (ESMO, 2003) 
6. Radiotherapy in metastatic prostate cancer 
For patients in which prostate cancer develops quickly with bony and/or other metastases 
and elevation of PSA, androgen deprivation is considered a therapeutic method of choice. It 
includes orchyectomy or TAB. Radiotherapy is considered only as palliative for painful 
bony metastases or threatening pathological fracture. 
Radiotherapy of bony metastases is mostly performed as local therapy to involved bones 
but sometimes it can be applied as half-body or total-body irradiation. For solitary or 
www.intechopen.com
 Prostate Cancer – Diagnostic and Therapeutic Advances 
 
190 
localized bony metastases radiotherapy is applied through simple fields (two opposed 
fields, single direct field etc). A higher daily dose of 2.5 Gy or 3 Gy is given. Single dose of 8 
Gy (single shoot), 20 Gy in 5 fractions or 30Gy in 10 fractions are considered to have the 
same results regarding pain relief and survival. 
Half-body irradiation is performed when there are many disseminated bony metastases and 
probably as many occult. The dose of 8 Gy is applied to lower half, and 6 Gy to upper half of 
the body. If we treat the whole body, the gap between irradiation of upper and lower half of 
the body is four weeks. (Samija et al., 1996) 
On the other hand, for patients with extensive locoregional prostate cancer, radiotherapy 
can be applied to pelvis with a total dose of 50-60Gy in order to reduce pain, hemathuria, 
urethral obstruction or lymphedema (Jelić, 2005) 
7. New radiation techniques 
The biological effect of ionizing radiation to cancer cells and normal tissues it based on the 
fact that the cancer cells are more susceptible to radiation because the lack of normal 
repair mechanism. Hypofractionated radiotherapy can reduce the duration of treatment 
since larger dose is given per day and the cumulative dose is adjusted to a lower dose. 
The randomized trials that compared hypofractionation with conventional RT did not 
have long enough follow-up and used to low total dose for current standards. But the 
investigation is still on. The extreme form of hypofractionation is stereotactic body 
radiotherapy (radiosurgery). This method uses only few fractions but with very high 
doses applied to a target volume in a very precise fashion. Although these techniques are 
attractive for theoretical advantage in radiobiology, the risk of late toxicity is 
considerable. 
Another possible radiotherapy approach to enhance radiotherapeutic ratio for prostate 
cancer is to utilize charged particles such as protons and carbon ions. The clinical benefit is 
still unclear but the optimism is based upon the fact that charged particles deposit most of 
their energy at a given depth followed by a dose fall-of with almost no dose deposition 
beyond the point of maximal dose called Bragg peak which can lead to increased normal 
tissue sparing. For proton therapy, a dosimetric analysis did not show a significant 
improvement in conformity to spare normal tissues over photon IMRT. Clinical outcome 
and toxicity is also similar. Carbon ion has the same dose distribution as proton beams with 
Bragg peak and following dose fall-of. But the relative biological effectiveness of carbon ion 
is four times higher than protons and photons that can lead to improved local tumor control 
without causing more toxicity. However these technologies are still developing and results 
are yet to be seen. (Choe & Liauw, 2010) 
8. Conclusion 
Radiotherapy is widely used as curative treatment modality for many cases of prostate 
cancer. There is a diverse array of radiotherapeutic strategies that can be effectively used to 
treat both organ-confined and locally advanced disease, alone or in combination with 
androgen-deprivation therapy. In recent decades it has undergone significant clinical and 
technological advances that aim to optimize cancer control outcomes while minimizing 
treatment morbidity. 
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